Cefditoren Side Effects
Medically reviewed by Drugs.com. Last updated on Apr 15, 2022.
Summary
Commonly reported side effects of cefditoren include: diarrhea. Other side effects include: vulvovaginal candidiasis and nausea. See below for a comprehensive list of adverse effects.
For the Consumer
Applies to cefditoren: oral tablets
Side effects include:
Diarrhea, nausea, headache, abdominal pain, vaginal moniliasis, dyspepsia, vomiting.
For Healthcare Professionals
Applies to cefditoren: oral tablet
General
In clinical trials, cefditoren has been well tolerated. Most adverse effects were mild and self-limiting, and the overall incidence was higher with increased dosage.[Ref]
Gastrointestinal
Gastrointestinal side effects have included diarrhea (up to 15%), nausea (up to 6%), abdominal pain (2%), dyspepsia (up to 2%), and vomiting (1%). Flatulence, pseudomembranous colitis, oral moniliasis, anorexia, constipation, dry mouth, eructation, flatulence, gastrointestinal disorder, increased appetite, stomatitis, and taste perversion have been reported in less than 1% of patients. Cephalosporins as a class have been associated with colitis.[Ref]
Onset of pseudomembranous colitis symptoms has been reported during or after antibacterial therapy.[Ref]
Dermatologic
Dermatologic side effects have included pruritus, rash, sweating, and urticaria in less than 1% of patients. Stevens-Johnson syndrome, erythema multiforme, and toxic epidermal necrolysis have been reported during postmarketing experience.[Ref]
Hypersensitivity
Hypersensitivity side effects have included allergic reaction (less than 1%). Anaphylaxis and anaphylactic shock been reported during postmarketing experience. Cephalosporins as a class have been associated with allergic reactions, anaphylaxis, Stevens-Johnson syndrome, serum sickness-like reaction, toxic epidermal necrolysis, and erythema multiforme. Patients allergic to other beta-lactam antibiotics may be allergic to cefditoren.[Ref]
Genitourinary
Genitourinary side effects have included vaginal moniliasis (up to 6%), hematuria (up to 3.1%), and increased urine white blood cells (2.3%). Proteinuria, leukorrhea, and vaginitis have been reported in less than 1% of patients.[Ref]
Hematologic
Hematologic side effects have included decreased hematocrit (up to 2.2%). Increased coagulation time, thrombocythemia, leukopenia, increased/decreased white blood cells, increased eosinophils, decreased neutrophils, increased lymphocytes, increased platelet count, decreased albumin, and decreased hemoglobin have been reported in less than 1% of patients. Thrombocytopenia has been reported during postmarketing experience. Cephalosporins as a class have been associated with aplastic anemia, hemolytic anemia, hemorrhage, prolonged prothrombin time, neutropenia, pancytopenia, and agranulocytosis.[Ref]
Hepatic
Hepatic side effects have included abnormal liver function tests, increased SGPT/ALT, and increased SGOT/AST in less than 1% of patients. Cephalosporins as a class have been associated with hepatic dysfunction (including cholestasis) and elevated bilirubin.[Ref]
Nervous system
Nervous system side effects have included headache (up to 3%). Somnolence and dizziness have been reported in less than 1% of patients. Several cephalosporins have been associated with seizures, particularly when inappropriately high doses were administered to renally impaired patients. Cephalosporins as a class have been associated with reversible hyperactivity and hypertonia.[Ref]
Metabolic
Metabolic side effects have included increased glucose (up to 1.8%). Decreased sodium, increased potassium, decreased chloride, decreased inorganic phosphorus, decreased calcium, increased cholesterol, hyperglycemia, and thirst have been reported in less than 1% of patients. Pivalate-containing compounds have been associated with clinically significant carnitine deficiency during prolonged use due to increased renal excretion of carnitine. Short-term treatment with cefditoren has not been associated with clinical effects of decreased carnitine levels. Cephalosporins as a class have been associated with elevated alkaline phosphatase and lactate dehydrogenase.[Ref]
Thirty percent and 46% decreases in serum carnitine levels were reported in patients after cefditoren 200 mg twice daily for 14 days and 400 mg twice daily for 14 days, respectively. Carnitine levels normalized within 7 days after discontinuation.[Ref]
Renal
Renal side effects have included increased BUN (less than 1%). Acute renal failure has been reported during postmarketing experience. Cephalosporins as a class have been associated with increased creatinine, renal dysfunction, and toxic nephropathy.[Ref]
Respiratory
Respiratory side effects have included asthma, pharyngitis, rhinitis, and sinusitis in less than 1% of patients. Interstitial pneumonia and acute eosinophilic pneumonia have been reported during postmarketing experience.[Ref]
Psychiatric
Psychiatric side effects have included abnormal dreams, insomnia, and nervousness in less than 1% of patients.[Ref]
Other
Other side effects have included asthenia, face edema, fever, fungal infection, peripheral edema, and pain in less than 1% of patients. Cephalosporins as a class have been associated with drug fever, superinfection, positive direct Coombs' test, and false-positive test for urinary glucose.[Ref]
Musculoskeletal
Musculoskeletal side effects have included myalgia (less than 1%). Arthralgia has been reported during postmarketing experience.[Ref]
More about cefditoren
- Drug interactions
- Dosage information
- During pregnancy or Breastfeeding
- Reviews (3)
- Imprints, shape & color data
- En español
- Drug class: third generation cephalosporins
Patient resources
Other brands
Professional resources
Related treatment guides
References
1. "Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc (2001):
2. Aguilar L, Barberdn J, Gimenez MJ, Coronel P, Gimeno M, Jose Granizo J "The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: A pooled analysis of seven clin" Clin Ther 28 (2006): 2061-9
3. "Product Information. Omnicef (cefdinir)." Parke-Davis (2001):
4. Mayer MD, Brass EP, Stickler TK, Hoppel CL, Mulford DJ "Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil." Clin Pharmacol Ther 73 (2003): 338-47
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.